Affiliation:
1. Saroj Gupta Cancer Centre and Research Institute.
Abstract
Aims & Objectives: To evaluate the response and toxicity with Conventional fractionation and hypofractionated radiotherapy for locally
advanced NSCLC following induction chemotherapy. To assess and compare following for locally advanced NSCLC with Conventional and hypo
fractionated radiotherapy following induction chemotherapy.
Materials And Methods: This prospective observational study was conducted at Saroj Gupta Cancer Centre and Research Institute, Kolkata;
accrual was from June 2016 to September 2017. Data was collected from all patients who had been cytological / histopathologically and
radiological proven stage III Non Small Cell Lung Carcinoma; fullling eligibility criteria, were recruited after obtaining informed consent.
Results And Analysis: We found that the association between response at the END OF RT in two groups was not statistically signicant
(p=0.8559). Association between Dermatitis highest grade at end of RT in two groups was not statistically signicant (p=0.5201). Association
between Response 6 months after RT in two groups was not statistically signicant (p=0.7667). Association between Response 9 months after RT
in two groups was not statistically signicant (p=0.9255). Association between Dermatitis.
Conclusion & Summary: Our study showed hypofractionated radiotherapy is non-inferior to Conventional radiotherapy with equivalent overall
response and toxicity and well tolerable.
In patients with poor performance status who cannot tolerate concurrent chemo radiation, induction chemotherapy with hypofractionated
radiotherapy regimen can be considered as a treatment of choice with manageable toxicities.
Reference11 articles.
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D et al. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107.
2. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Retrieved fromhttp://globocan.iarc.fr/ Pages/fact_sheets_ Cancer.aspx
3. Behera, D; Balamugesh T "Lung cancer in India" Indian Journal of Chest Diseases and Allied Sciences (2004); 46 (4): 269–81.
4. Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011 Oct 5;103(19):1452-60. doi: 10.1093/jnci/djr325. Erratum in: J Natl Cancer Inst. 2012 Jan 4;104(1):79. PubMed PMID: 21903745.
5. Nobuyuki Yamamoto, Kazuhiko Nakagawa, Yasumasa Nishimura, Kayoko Tsujino, Miyako Satouchi, Shinzoh Kudo et al. Phase III Study Comparing Second- and Third-Generation Regimens with Concurrent Thoracic Radiotherapy in Patients with Unresectable Stage III Non–Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol2010; 28(23):3739-45.